SloveniaHOYA Lens Singapore has introduced the MiYOSMART iQ TF, a new myopia control spectacle lens that combines D.I.M.S. Technology with the Triple Enhanced Design (TED). Clinical trials involving 196 children aged 4 to 12 in Hong Kong showed that 90% of participants experienced no clinically significant myopia progression after 12 months of use. The study highlights the importance of early intervention in managing myopia, especially in young children whose eyes are still developing. The lens aims to provide effective non-invasive treatment options for parents seeking to manage their children’s myopia progression. HOYA Vision Care emphasizes the significance of this advancement in improving vision care and reducing the long-term impacts of myopia.
Bias read (Center): The article discusses a medical product launch and clinical trial results related to myopia control, which is a health-related issue rather than a politically charged topic. There is no indication of political bias or framing in the content. The focus remains on scientific and medical advancements,故
.jpg%3Fwidth%3D1200%26auto%3Dwebp%26trim%3D381%252C760%252C3083%252C699&w=3840&q=75&output=webp&we)
